HK1216852A1 - -糖蛋白抑制劑治療鼻竇炎 - Google Patents

-糖蛋白抑制劑治療鼻竇炎

Info

Publication number
HK1216852A1
HK1216852A1 HK16104837.1A HK16104837A HK1216852A1 HK 1216852 A1 HK1216852 A1 HK 1216852A1 HK 16104837 A HK16104837 A HK 16104837A HK 1216852 A1 HK1216852 A1 HK 1216852A1
Authority
HK
Hong Kong
Prior art keywords
rhinosinusitis
treatment
glycoprotein inhibitors
glycoprotein
inhibitors
Prior art date
Application number
HK16104837.1A
Other languages
English (en)
Inventor
Benjamin S Bleier
Original Assignee
Massachusetts Eye & Ear Infirmary
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Eye & Ear Infirmary filed Critical Massachusetts Eye & Ear Infirmary
Publication of HK1216852A1 publication Critical patent/HK1216852A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polymers & Plastics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16104837.1A 2012-12-27 2016-04-27 -糖蛋白抑制劑治療鼻竇炎 HK1216852A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261746290P 2012-12-27 2012-12-27
PCT/US2013/077945 WO2014106021A1 (en) 2012-12-27 2013-12-27 Treatment of rhinosinusitis with p-glycoprotein inhibitors

Publications (1)

Publication Number Publication Date
HK1216852A1 true HK1216852A1 (zh) 2016-12-09

Family

ID=51022073

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16104837.1A HK1216852A1 (zh) 2012-12-27 2016-04-27 -糖蛋白抑制劑治療鼻竇炎

Country Status (5)

Country Link
US (5) US9744210B2 (zh)
EP (2) EP2938339B1 (zh)
CA (1) CA2928035A1 (zh)
HK (1) HK1216852A1 (zh)
WO (1) WO2014106021A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014106021A1 (en) * 2012-12-27 2014-07-03 Massachusetts Eye & Ear Infirmary Treatment of rhinosinusitis with p-glycoprotein inhibitors
JP7085485B2 (ja) * 2016-01-15 2022-06-16 マサチューセッツ アイ アンド イヤー インファーマリー 分泌型ｐ－糖タンパク質は、慢性鼻副鼻腔炎の非侵襲的バイオマーカーである
AU2018301500A1 (en) 2017-07-14 2020-01-30 University Of Bath Methods and compositions for treating inflammation
JP7482874B2 (ja) 2018-08-22 2024-05-14 バカイン バイオセラピューティクス， リミテッド シクロスポリン組成物および使用方法
US20220168260A1 (en) * 2019-03-25 2022-06-02 Massachusetts Eye And Ear Infirmary Methods and Compositions to Treat and Diagnose Diseases or Pathologies Associated with Inflammation of the Sinuses and Nasal Cavity
KR20230026460A (ko) * 2020-06-21 2023-02-24 매사추세츠 아이 앤드 이어 인퍼머리 만성 비부비동염 치료를 위한 조합 베라파밀 및 모메타손 요법

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1603758A (en) 1925-02-12 1926-10-19 Adela B Fisher Nasal suction irrigator
US1856811A (en) 1931-07-11 1932-05-03 Hooichi Sumida Nasal irrigator
US2989437A (en) * 1955-06-08 1961-06-20 Upjohn Co Anti-inflammatory and anti-bacterial decongestant nasal spray compositions
US3847145A (en) 1973-04-13 1974-11-12 M Grossan Nasal irrigation system
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5898037A (en) * 1992-11-13 1999-04-27 Marx; Alvin J. Formulations of magnesium compounds for local application and methods of treatment using the same
IT1275907B1 (it) 1995-03-14 1997-10-24 Mefar Srl Dispositivo a doccia micronizzata per il lavaggio delle cavita' nasali e limitrofe
GB9605074D0 (en) * 1996-03-11 1996-05-08 Chiroscience Ltd Dosage forms and uses
US6238377B1 (en) 1997-01-27 2001-05-29 Jin-Zhou Liu Nasal-nasopharyngeal cleaning system
US6451815B1 (en) * 1997-08-14 2002-09-17 Aventis Pharmaceuticals Inc. Method of enhancing bioavailability of fexofenadine and its derivatives
DE19903165A1 (de) 1999-01-27 2000-08-03 Mann & Hummel Filter Ansaugvorrichtung mit einem Durchbrüche aufweisenden Leitungsabschnitt
WO2001058470A2 (en) 2000-02-11 2001-08-16 Praecis Pharmaceuticals Incorporated Methods for enhancing the bioavailability of a drug
US6328718B1 (en) 2000-04-29 2001-12-11 Chien-Li Chen Snivel sucker
AU2001282988B2 (en) * 2000-07-26 2006-01-05 Atopic Pty Ltd Methods for treating atopic disorders
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US6579898B2 (en) * 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
US20080199522A1 (en) * 2001-04-12 2008-08-21 Astellas Pharma, Inc. Timed-release compression-coated solid composition for oral administration
AU2002322520A1 (en) 2001-07-17 2003-03-03 Kerberos Proximal Solutions Fluid exchange system for controlled and localized irrigation and aspiration
US6907879B2 (en) 2002-02-04 2005-06-21 Ndt Agent delivery and aspiration device
US8003106B2 (en) * 2002-03-13 2011-08-23 Kyowa Hakko Kirin Co., Ltd. Human monoclonal antibodies to influenza M2 protein and methods of making and using same
AU2004222340B2 (en) * 2003-03-14 2009-11-12 Intersect Ent, Inc. Sinus delivery of sustained release therapeutics
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
CA2533846C (en) 2003-07-29 2012-08-28 Universitaetsklinikum Muenster Means and methods for treating a disease which is associated with an excess transport of hyaluronan across a lipid bilayer
US20070020299A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
DK1711164T3 (da) 2004-01-21 2010-07-19 Schering Corp Fremgangsmåde til behandling af akut rhinosinusitis
WO2005089670A1 (en) * 2004-03-15 2005-09-29 Durect Corporation Pharmaceutical compositions for administration to a sinus
US7361168B2 (en) * 2004-04-21 2008-04-22 Acclarent, Inc. Implantable device and methods for delivering drugs and other substances to treat sinusitis and other disorders
FR2877579B1 (fr) 2004-11-09 2007-01-19 Jose Bensoussan Dispositif d'aspiration de secretions nasales
GB0426188D0 (en) * 2004-11-30 2004-12-29 Leuven K U Res & Dev DNA repeats
JP4881874B2 (ja) * 2004-12-06 2012-02-22 協和発酵キリン株式会社 インフルエンザｍ２タンパク質に対するヒトモノクローナル抗体及びその生産方法及びその使用
US20060134009A1 (en) * 2004-12-16 2006-06-22 Daniel Deaver Low dose corticosteroid powders for inhalation
US8524735B2 (en) * 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US20070009533A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism
JP2009500356A (ja) * 2005-07-07 2009-01-08 エラン ファーマ インターナショナル リミテッド ナノ粒子クラリスロマイシン製剤
WO2007012052A1 (en) * 2005-07-20 2007-01-25 Medical College Of Georgia Research Institute Use of protein profiles in disease diagnosis and treatment
US20070226012A1 (en) * 2005-12-13 2007-09-27 Naryx Pharma, Inc. Methods of measuring symptoms of chronic rhinosinusitis
EP1808173A1 (en) * 2006-01-12 2007-07-18 Matthias Dormeyer Use of CNS penetrating anticancer compounds for the treatment of protozan diseases
US7888049B2 (en) * 2006-02-07 2011-02-15 Toxcure. LLC Rapid nasal assay kit
EP2851064A3 (en) * 2006-07-11 2015-08-05 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
WO2008022146A2 (en) 2006-08-14 2008-02-21 Wayne State University Polymer-surfactant nanoparticles for sustained release of compounds
US7959597B2 (en) 2006-11-06 2011-06-14 Aardvark Medical, Llc Irrigation and aspiration device and method
US8048023B2 (en) 2007-03-06 2011-11-01 Rhinosystems Inc. Systems and methods for nasal irrigation
CN101380328B (zh) * 2007-09-03 2010-08-04 李想 一种治疗鼻炎的药物及其制备方法
US7862548B2 (en) 2008-02-13 2011-01-04 Bekan Rhinologics Inc. Nasal irrigation device
AU2009246543B2 (en) * 2008-05-13 2015-08-06 Clarassance, Inc. Recombinant human CC10 and compositions thereof for use in the treatment of nasal rhinitis
US20100137235A1 (en) * 2008-10-15 2010-06-03 Mutual Pharmaceutical Company, Inc. Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics
US7820681B1 (en) 2009-01-14 2010-10-26 Mutual Pharmaceutical Company, Inc. Methods for concomitant administration of colchicine and a second active agent
US20140336463A1 (en) * 2009-03-16 2014-11-13 Alan H. Shikani Rhinotopic therapy for the treatment of chronic rhinosinusitis biofilm disruption, treatment of mucosal granulation and sinus polyps
PE20121646A1 (es) * 2009-11-04 2012-12-02 Merck Sharp & Dohme Anticuerpo anti-tslp modificado por tecnicas de ingeneria genetica
US8162921B2 (en) 2009-12-08 2012-04-24 Medinvent, Llc Method and device for nasal irrigation and drug delivery
DK2547964T3 (en) * 2010-03-16 2016-06-06 Airsonett Ab Treatment of asthma, allergic rhinitis and improving sleep quality through temperature controlled laminar airflow treatment
WO2011137516A1 (en) * 2010-05-03 2011-11-10 The Royal Institution For The Advancement Of Learning / Mcgill University Flavonoid dimers and their use
WO2012006599A2 (en) 2010-07-09 2012-01-12 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of rhinosinusitis and nasal polyposis
AR082803A1 (es) * 2010-09-01 2013-01-09 Portola Pharm Inc Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p
BR112013027779A2 (pt) 2011-04-28 2017-02-21 C Mehta Ketan ponta para enxágue nasal
US20130071335A1 (en) * 2011-09-20 2013-03-21 Elliott C. Lasser X-ray contrast media compositions and methods of using the same
WO2013112865A1 (en) * 2012-01-27 2013-08-01 The Trustees Of The University Of Pennsylvania Diagnosis and treatment for respiratory tract diseases
WO2014106021A1 (en) 2012-12-27 2014-07-03 Massachusetts Eye & Ear Infirmary Treatment of rhinosinusitis with p-glycoprotein inhibitors
JP7085485B2 (ja) * 2016-01-15 2022-06-16 マサチューセッツ アイ アンド イヤー インファーマリー 分泌型ｐ－糖タンパク質は、慢性鼻副鼻腔炎の非侵襲的バイオマーカーである
WO2018071810A1 (en) 2016-10-13 2018-04-19 RhinoNase, Inc. Antibiotic compositions for nasal irrigation and methods
WO2019139901A1 (en) 2018-01-12 2019-07-18 Massachusetts Eye And Ear Infirmary Nasal exosomes for non-invasive sampling of cns proteins
US20220168260A1 (en) 2019-03-25 2022-06-02 Massachusetts Eye And Ear Infirmary Methods and Compositions to Treat and Diagnose Diseases or Pathologies Associated with Inflammation of the Sinuses and Nasal Cavity

Also Published As

Publication number Publication date
US20200197481A1 (en) 2020-06-25
EP2938339A4 (en) 2016-07-06
US11007246B2 (en) 2021-05-18
US11786574B2 (en) 2023-10-17
US10653745B2 (en) 2020-05-19
EP3789022A1 (en) 2021-03-10
US20160193286A1 (en) 2016-07-07
US9744210B2 (en) 2017-08-29
EP2938339B1 (en) 2020-08-19
WO2014106021A1 (en) 2014-07-03
EP2938339A1 (en) 2015-11-04
CA2928035A1 (en) 2014-07-03
US20240148823A1 (en) 2024-05-09
US20210330737A1 (en) 2021-10-28
US20170348384A1 (en) 2017-12-07

Similar Documents

Publication Publication Date Title
EP2723384A4 (en) TREATMENT OF PROTEINOPATHIES
EP2670434A4 (en) TREATMENT OF TAUOPATHIA
HK1207574A1 (zh) 骨髓抑制的治療
EP2717855A4 (en) PROCESSING METHODS
HK1205759A1 (zh) 生物質量的處理
IL234813A0 (en) Methods for increasing the efficacy of cd37-based therapy
HK1216852A1 (zh) -糖蛋白抑制劑治療鼻竇炎
ZA201403739B (en) Methods of treatment with deferiprone
GB2511470B (en) Treatment of fungal infections using alternative oxidase inhibitors
HK1202053A1 (zh) 肝臟狀況的治療
HK1201066A1 (zh) 端錨聚合酶的吡喃並吡啶酮抑制劑
GB201309274D0 (en) Treatment Of Fuel
IL237862A0 (en) Methods to reduce the formation of scale
HK1199737A1 (zh) 煤炭加工
PL2888228T3 (pl) Inhibitory oddziaływania CD40-TRAF6
EP2892529A4 (en) USES OF (-) - PERHEXILINE
GB201207907D0 (en) Treatment of depression
EP2908871A4 (en) ABSTRACT PROCESSING TECHNIQUES
GB201221118D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment
IL233740A0 (en) Treatment of liver diseases
GB201206326D0 (en) Methods of treatment
GB201206324D0 (en) Methods of treatment
GB201206325D0 (en) Methods of treatment